Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-19

Study Completion Date

2021-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial studies the efficacy of trastuzumab treatment in breast cancer patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors and HER2-expressing bone marrow disseminated tumor cells (DTCs). Administering targeted trastuzumab therapy to these patients may result in the elimination of HER2 expressing disseminated tumor cells and improved disease free survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

NCT00726180

Breast Cancer

TERMINATED PHASE1/PHASE2

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

NCT02229149

Breast Neoplasms Malignant Tumor of the Breast

TERMINATED PHASE2

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

NCT00118053

Breast Cancer

TERMINATED PHASE2

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

NCT02586025

Breast Cancer

COMPLETED PHASE3

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

NCT00251433

Neoplasms, Breast

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (definitive therapy)

Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:

* doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel
* docetaxel plus cyclophosphamide
* single-agent paclitaxel
* docetaxel plus carboplatin
* fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel

Group Type ACTIVE_COMPARATOR

Doxorubicin

Intervention Type DRUG

Cyclophosphamide

Intervention Type DRUG

Paclitaxel

Intervention Type DRUG

Epirubicin

Intervention Type DRUG

Docetaxel

Intervention Type DRUG

Fluorouracil

Intervention Type DRUG

Arm II (definitive therapy, trastuzumab)

Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:

* doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel
* docetaxel plus cyclophosphamide
* single-agent paclitaxel
* docetaxel plus carboplatin
* fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel

Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Doxorubicin

Intervention Type DRUG

Trastuzumab

Intervention Type BIOLOGICAL

Cyclophosphamide

Intervention Type DRUG

Paclitaxel

Intervention Type DRUG

Epirubicin

Intervention Type DRUG

Docetaxel

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Fluorouracil

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doxorubicin

Intervention Type DRUG

Trastuzumab

Intervention Type BIOLOGICAL

Cyclophosphamide

Intervention Type DRUG

Paclitaxel

Intervention Type DRUG

Epirubicin

Intervention Type DRUG

Docetaxel

Intervention Type DRUG

Carboplatin

Intervention Type DRUG

Fluorouracil

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Adriamycin®, Rubex®, Hydroxydaunomycin Hydrochloride, Hydroxydoxorubicin Hydrochloride •Herceptin® Cytoxan®, CPM, CTX, CYT Abraxane®, Onxol® Ellence, Pharmorubicin, Epirubicin ebewe Taxotere, Docefrez cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Paraplatin, Paraplatin-AQ 5-FU, Adrucil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed HER2-negative primary invasive ductal or invasive lobular breast carcinoma. For patients enrolling for neoadjuvant treatment, diagnosis must be clinical stage II or III; for patients enrolling for adjuvant treatment, diagnosis must be pathologic stage IIA to IIIC. Standard HER2 testing will be performed in the surgical specimen at Washington University according to the standard of care in the Department of Pathology. A HER2-negative primary breast cancer sample from a patient eligible for randomization should have a HER2 IHC score of 0 or 1+ Those patients with IHC score of 2+ should be HER2 FISH-negative in standard testing. Patient will have undergone staging studies including a CT of the chest/abdomen/pelvis and bone scan and/or PET scan either prior to the initiation of treatment or prior to entry into the trial. In addition, patients with non-metastatic, HER2-negative, recurrent tumors who need chemotherapy are eligible.
* Planning to receive best practice adjuvant or neoadjuvant chemotherapy according to institutional guidelines. Adjuvant tamoxifen or aromatase inhibitors treatment will be allowed for hormone receptor-positive patients. Patients who have failed neoadjuvant endocrine therapy will also be eligible.
* At least 18 years old.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
* Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document.

* Presence of bone marrow ERBB2 overexpressing DTCs at the time of diagnosis; bone marrow aspiration will be performed in consented patients to evaluate DTCs following pre-registration provided patients meet all eligibility criteria as described in this section.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
* Adequate cardiac function as demonstrated by LVEF of \>55% performed no more than 4 weeks prior to randomization.
* Normal organ and marrow function as defined below:

* leukocytes ≥3,000/mcL
* absolute neutrophil count ≥1,500/mcL
* platelets ≥100,000/mcL
* hemoglobin ≥ 10 g/dL
* total bilirubin within institutional upper limits of normal unless related to primary disease
* AST(SGOT)/ALT(SGPT) ≤2.0 X institutional upper limit of normal
* Creatinine ≤ 1.5 institutional upper limits of normal OR creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
* If a woman of childbearing potential, patient must use two forms of effective contraception for a minimum of 6 months following trastuzumab. Effective methods of birth control include use of established oral, injected, or implanted hormonal methods of birth control, IUD, IUS, and condoms.

Exclusion Criteria

* Prior chemotherapy for this cancer (excluding initiation of best practice chemotherapy to be given as standard of care as described in this protocol, which may be initiated after the pre-registration bone marrow collection but before final confirmation of eligibility and randomization).
* Previous treatment with trastuzumab or any other Her2 targeted therapy.
* Presence of an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

* Evidence of distant metastasis present by CT scan, bone scan, or physical exam.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to trastuzumab.
* Prior chemotherapy for this cancer (excluding initiation of best practice chemotherapy to be given as standard of care described in this protocol, which may be initiated after the pre-registration bone marrow collection but before final confirmation of eligibility and randomization).
* History of other malignancy ≤ 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.
* Pregnant or breastfeeding. Patient must have a negative serum pregnancy test ≤ 7 days from date of registration (if a woman of childbearing potential).
* Clinically important history of active liver disease, including viral or other hepatitis or cirrhosis.
* Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia defined as less than the lower limit of normal for the institution despite adequate electrolyte supplementation.
* Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No